Description
The Firm has identified a lead compound with novel target to be developed into a potential therapeutic for triple-negative breast cancers (TNBC). This project seeks to develop an advanced formulation for delivery, evaluate the performance…
Amendment chain · 5 entries
Each notch is one published row for this agreement: #0 is the original (placed at its start date) and each later notch is an amendment (placed at its amendment date). The height is the agreement's total value as of that row — the source column is cumulative, not a change amount — so the line reads as the commitment over time and the right-most notch is the current commitment shown in the header. For this agreement: $400,948 at start, $481,596 after amendment #5 (+$80,648).
- #02019-07-01$400,948
- #12019-11-19$451,896+$50,948
- #32020-03-31$461,596+$9,700
- #42020-10-01$461,596
- #52021-03-22$481,596+$20,000
| Row | Date | Total value as of row | Change vs previous | Description on this row |
|---|---|---|---|---|
| #0 original | 2019-07-01(start date) | $400,948 | — | The Firm has identified a lead compound with novel target to be developed into a potential therapeutic for tri… |
| #1 amendment | 2019-11-19 | $451,896 | +$50,948 | The Firm has identified a lead compound with novel target to be developed into a potential therapeutic for tri… |
| #3 amendment | 2020-03-31 | $461,596 | +$9,700 | The Firm has identified a lead compound with novel target to be developed into a potential therapeutic for tri… |
| #4 amendment | 2020-10-01 | $461,596 | +$0 | The Firm has identified a lead compound with novel target to be developed into a potential therapeutic for tri… |
| #5 amendment | 2021-03-22 | $481,596 | +$20,000 | The Firm has identified a lead compound with novel target to be developed into a potential therapeutic for tri… |
Related records · 9
Records are related by an explicit link in the data, stated for each group below — never by text similarity. Values are each agreement's current commitment (latest amendment).
Other current agreements for the same recipient (business number 808104087)
| Ref | Department · program | Current value | FY |
|---|---|---|---|
| 172-2020-2021-Q4-966130 | National Research Council Canada | Conseil national de recherches Canada · Industrial Research Assistance Program – Innovation Assistance Program | $5,419 | FY2021 |
| 172-2020-2021-Q3-960440 | National Research Council Canada | Conseil national de recherches Canada · Industrial Research Assistance Program – Innovation Assistance Program | $12,176 | FY2021 |
| 172-2020-2021-Q1-950245 | National Research Council Canada | Conseil national de recherches Canada · Innovation Assistance Program | $10,164 | FY2021 |
| 172-2018-2019-Q1-904717 | National Research Council Canada | Conseil national de recherches Canada · Industrial Research Assistance Program – Contributions to Firms | $500,000 | FY2019 |
Other recipients funded under "Industrial Research Assistance Program – Contributions to Firms" by National Research Council Canada | Conseil national de recherches Canada (most recent first)
| Ref | Recipient | Fiscal year | Current value | FY |
|---|---|---|---|---|
| 172-2025-2026-Q2-1034675 | Mediphage Bioceuticals, Inc. | FY2027 | $63,380 | FY2027 |
| 172-2025-2026-Q3-1037522 | OBKIO INC. | FY2026 | $50,000 | FY2026 |
| 172-2025-2026-Q3-1037889 | SERVICES DE DEVELOPPEMENT PROFESSIONELS SDP INC | FY2026 | $25,000 | FY2026 |
| 172-2025-2026-Q2-1034040 | Griffith Foods Limited | FY2026 | $54,880 | FY2026 |
| 172-2025-2026-Q3-1037273 | Apollo Machine & Welding Ltd. | FY2026 | $230,000 | FY2026 |
Cite as: Glassbox record view · Federal grants & contributions · 172-2019-2020-Q2-931368 · retrieved 2026-11-15.